Table 4.
The Potential Prognostic Indicators of Overall Survival for Breast Cancer Patients with Liver Metastasis After Surgery
| Characteristics | Group | Univariate | 95% CI | Multivariate | 95% CI | ||||
|---|---|---|---|---|---|---|---|---|---|
| P | HR | Low | High | P | HR | Low | High | ||
| aMAP | Low | 1(Ref.) | 1(Ref.) | ||||||
| High | 0.001 | 3.745 | 1.727 | 8.120 | 0.000 | 2.312 | 1.495 | 3.573 | |
| Age | <49 | 1(Ref.) | |||||||
| ≥49 | 0.955 | 1.023 | 0.465 | 2.252 | |||||
| BMI | <23.51 | 1(Ref.) | |||||||
| ≥23.51 | 0.142 | 1.494 | 0.875 | 2.551 | |||||
| Family history | No | 1(Ref.) | |||||||
| Yes | 0.911 | 1.035 | 0.562 | 1.905 | |||||
| Menarche age | <14 | 1(Ref.) | 1(Ref.) | ||||||
| ≥14 | 0.004 | 2.562 | 1.360 | 4.826 | 0.001 | 2.236 | 1.416 | 3.532 | |
| Menopause | No | 1(Ref.) | |||||||
| Yes | 0.566 | 1.296 | 0.535 | 3.141 | |||||
| ALT | <17 | 1(Ref.) | |||||||
| ≥17 | 0.353 | 0.728 | 0.372 | 1.424 | |||||
| AST | <20 | 1(Ref.) | |||||||
| ≥20 | 0.442 | 1.331 | 0.642 | 2.757 | |||||
| ALB | <44.1 | 1(Ref.) | 1(Ref.) | ||||||
| ≥44.1 | 0.002 | 0.339 | 0.170 | 0.677 | 0.037 | 0.648 | 0.432 | 0.974 | |
| CRP | <0.07 | 1(Ref.) | |||||||
| ≥0.07 | 0.935 | 0.975 | 0.526 | 1.805 | |||||
| DBIL | <2.75 | 1(Ref.) | |||||||
| ≥2.75 | 0.593 | 0.844 | 0.453 | 1.572 | |||||
| CHOL | <3.80 | 1(Ref.) | |||||||
| ≥3.80 | 0.634 | 1.173 | 0.608 | 2.260 | |||||
| TG | <1.16 | 1(Ref.) | |||||||
| ≥1.16 | 0.197 | 0.680 | 0.379 | 1.221 | |||||
| TP | <73.0 | 1(Ref.) | |||||||
| ≥73.0 | 0.593 | 1.211 | 0.599 | 2.448 | |||||
| G | <29.0 | 1(Ref.) | |||||||
| ≥29.0 | 0.087 | 0.578 | 0.309 | 1.083 | |||||
| PAB | <27.0 | 1(Ref.) | |||||||
| ≥27.0 | 0.210 | 1.453 | 0.811 | 2.604 | |||||
| CA125 | <10.57 | 1(Ref.) | |||||||
| ≥10.57 | 0.909 | 0.961 | 0.487 | 1.896 | |||||
| CA153 | <13.01 | 1(Ref.) | |||||||
| ≥13.01 | 0.080 | 1.608 | 0.944 | 2.739 | |||||
| CEA | <1.95 | 1(Ref.) | |||||||
| ≥1.95 | 0.173 | 0.683 | 0.394 | 1.182 | |||||
| D-D | <0.21 | 1(Ref.) | |||||||
| ≥0.21 | 0.357 | 0.757 | 0.419 | 1.368 | |||||
| FIB | <2.75 | 1(Ref.) | |||||||
| ≥2.75 | 0.567 | 0.848 | 0.483 | 1.490 | |||||
| White blood cell | <5.45 | 1(Ref.) | |||||||
| ≥5.45 | 0.119 | 1.356 | 0.925 | 1.989 | |||||
| Neutrophils | <3.23 | 1(Ref.) | 1(Ref.) | ||||||
| ≥3.23 | 0.002 | 3.845 | 1.645 | 8.989 | 0.494 | 1.159 | 0.759 | 1.771 | |
| Lymphocyte | <1.70 | 1(Ref.) | |||||||
| ≥1.70 | 0.102 | 1.702 | 0.900 | 3.217 | |||||
| Monocyte | <0.35 | 1(Ref.) | 1(Ref.) | ||||||
| ≥0.35 | 0.015 | 2.139 | 1.156 | 3.959 | 0.005 | 1.769 | 1.183 | 2.646 | |
| Platelet | <233 | 1(Ref.) | |||||||
| ≥233 | 0.782 | 0.916 | 0.491 | 1.707 | |||||
| Type of surgery | Mastectomy | 1(Ref.) | |||||||
| Breast-conserving surgery | 0.935 | 0.945 | 0.237 | 3.760 | |||||
| Pathological tumor size | ≤2cm | 1(Ref.) | |||||||
| >2 and ≤5cm | 0.759 | 0.910 | 0.499 | 1.660 | |||||
| >5cm | 0.178 | 1.923 | 0.743 | 4.974 | |||||
| Histologic grade | I | 1(Ref.) | |||||||
| II | 0.098 | 2.923 | 0.821 | 10.415 | |||||
| III | 0.380 | 1.841 | 0.472 | 7.180 | |||||
| Pathological TNM stage | I | 1(Ref.) | |||||||
| II | 0.384 | 1.661 | 0.530 | 5.205 | |||||
| III | 0.701 | 0.766 | 0.196 | 2.988 | |||||
| TLN | <19 | 1(Ref.) | |||||||
| ≥19 | 0.433 | 0.859 | 0.588 | 1.255 | |||||
| PLN | <5 | 1(Ref.) | |||||||
| ≥5 | 0.109 | 2.072 | 0.850 | 5.051 | |||||
| ER | Negative | 1(Ref.) | 1(Ref.) | ||||||
| Positive | 0.007 | 0.196 | 0.060 | 0.641 | 0.309 | 0.606 | 0.231 | 1.589 | |
| PR | Negative | 1(Ref.) | |||||||
| Positive | 0.425 | 0.699 | 0.290 | 1.685 | |||||
| HER2 | Negative | 1(Ref.) | |||||||
| Positive | 0.576 | 0.839 | 0.454 | 1.550 | |||||
| Ki67 | Negative | 1(Ref.) | |||||||
| Positive | 0.435 | 0.764 | 0.389 | 1.500 | |||||
| AR | Negative | 1(Ref.) | |||||||
| Positive | 0.679 | 0.630 | 0.070 | 5.632 | |||||
| CK5/6 | Negative | 1(Ref.) | |||||||
| Positive | 0.538 | 1.325 | 0.540 | 3.253 | |||||
| E-cad | Negative | 1(Ref.) | |||||||
| Positive | 0.178 | 1.328 | 0.879 | 2.006 | |||||
| EGFR | Negative | 1(Ref.) | |||||||
| Positive | 0.474 | 0.622 | 0.170 | 2.279 | |||||
| P53 | Negative | 1(Ref.) | |||||||
| Positive | 0.282 | 1.410 | 0.755 | 2.633 | |||||
| TOP2A | Negative | 1(Ref.) | |||||||
| Positive | 0.316 | 0.615 | 0.238 | 1.590 | |||||
| Lymph vessel invasion | Negative | 1(Ref.) | |||||||
| Positive | 0.088 | 1.633 | 0.929 | 2.871 | |||||
| Neural invasion | Negative | 1(Ref.) | |||||||
| Positive | 0.686 | 1.152 | 0.581 | 2.285 | |||||
| Postoperative chemotherapy | No | 1(Ref.) | |||||||
| Yes | 0.741 | 0.923 | 0.572 | 1.487 | |||||
| Postoperative radiotherapy | No | 1(Ref.) | |||||||
| Yes | 0.146 | 0.613 | 0.316 | 1.186 | |||||
| Postoperative endocrine therapy | No | 1(Ref.) | 1(Ref.) | ||||||
| Yes | 0.000 | 0.377 | 0.251 | 0.567 | 0.006 | 0.466 | 0.269 | 0.807 | |
| Postoperative targeted therapy | No | 1(Ref.) | |||||||
| Yes | 0.975 | 1.012 | 0.486 | 2.105 | |||||
Abbreviations: BMI, body mass index; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; ALB, Albumin; CRP, C-reactive protein; TBIL, Total bilirubin; DBIL, Direct bilirubin; IBIL, Indirect bilirubin; CHOL, Cholesterol; TG, Triglyceride; TP, Total protein; G, Globulin; PAB, Prealbumin; CA125, Carbohydrate antigen 125; CA153, Carbohydrate antigen 153; CEA, Carcinoembryonic antigen; DD, D-Dimer; FIB, Fibrinogen; TLN, Total lymph nodes; PLN, Positive lymph nodes; ER, estrogen receptor; PR, progesterone receptor; HER2, Human Epidermal Growth Factor Receptor 2; AR, androgen receptor; CK5/6, Cytokeratin 5/6; E-cad, E-cadherin; EGFR, Epidermal Growth Factor Receptor; TOP2A, topoisomerase 2A.